Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30985266 | 1.00 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL11128153 | 1.00 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL6228812 | 0.91 | TSHR (0.61) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL753828 | 0.83 | TSHR (0.56) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL29259384 | 0.82 | TSHR (0.50) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL19770563 | 0.82 | TSHR (0.50) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL22398871 | 0.82 | TSHR (0.35) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL121146 | 0.82 | TSHR (0.57) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL3502791 | 0.82 | TSHR (0.82) | TSHRLMNAALDH1A1RECQLEPHX2 | |
| SCHEMBL3503395 | 0.82 | TSHR (0.82) | TSHRLMNAALDH1A1RECQLEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240222629-A1 | SECONDARY BATTERY AND MANUFACTURING METHOD THEREOF | SEMICONDUCTOR ENERGY LAB (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20180076489-A1 | ELECTRODE AND POWER STORAGE DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180019462-A1 | Graphene Compound, Method for Forming Graphene Compound, and Power Storage Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180076489-A1 | ELECTRODE AND POWER STORAGE DEVICE | SELENOI, SOD1, L1CAM | TSHR 4737/4885LMNA 585/4885ALDH1A1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.